Development and validation of the crohn’s disease patient-reported outcomes signs and symptoms (CD-PRO/SS) diary

被引:35
|
作者
Higgins P.D.R. [1 ,6 ]
Harding G. [2 ]
Leidy N.K. [2 ]
Debusk K. [3 ]
Patrick D.L. [4 ]
Viswanathan H.N. [5 ,7 ]
Fitzgerald K. [3 ]
Donelson S.M. [3 ]
Cyrille M. [5 ]
Ortmeier B.G. [5 ]
Wilson H. [2 ]
Revicki D.A. [2 ]
Globe G. [5 ]
机构
[1] University of Michigan, Ann Arbor, MI
[2] Evidera, Bethesda, MD
[3] Genentech Inc, South San Francisco, CA
[4] University of Washington, Seattle, WA
[5] Amgen Inc, Thousand Oaks, CA
[6] University of Michigan, SPC 5682, 1650 West Medical Center Drive, Ann Arbor, 48109, MI
[7] Allergan Inc, Irvine, CA
关键词
Clinical trial endpoints; Crohn’s disease; Patient-reported outcome; Reliability; Signs and symptoms; Validity;
D O I
10.1186/s41687-018-0044-7
中图分类号
学科分类号
摘要
Background: The clinical course of Crohn’s disease (CD) and the effect of its treatment are monitored through patient-reported signs and symptoms (S&S), and endoscopic evidence of inflammation. The Crohn’s Disease Patient-reported Outcomes Signs and Symptoms (CD-PRO/SS) measure was developed to standardize the quantification of gastrointestinal S&S of CD through direct report from patient ratings. Methods: The CD-PRO/SS was developed based on data from concept elicitation (focus groups, interviews; n = 29), then refined through cognitive interviews of CD patients (n = 20). Measurement properties, including item-level statistics, scaling structure, reliability, and validity, were examined using secondary analyses of baseline and two-week clinical trial data of adults with moderate-to-severe CD (n = 238). Results: Findings from qualitative interviews identified nine S&S items covering bowel and abdominal symptoms. The final CD-PRO/SS daily diary includes two scales: Bowel S&S (three items) and Abdominal Symptoms (three items), each scored separately. Each scale showed evidence of adequate reliability (α = 0.74 and 0.67, respectively); reproducibility (intraclass correlation coefficient > 0.80), and validity, with the last including moderate correlations with the Inflammatory Bowel Disease Questionnaire bowel symptom score and select items (ranging from r = 0.43– 0.54). Scores distinguished patients categorized by patient global ratings of disease severity (p < 0.0001). Conclusions: Results suggest the CD-PRO/SS is a reliable and valid measure of gastrointestinal symptom severity in CD patients. Additional longitudinal data are needed to evaluate the ability of the CD-PRO/SS scores to detect responsiveness and inform the selection of responder definitions. © The Author(s). 2018 Open Access.
引用
收藏
相关论文
共 50 条
  • [1] Development of the Crohn's Disease Patient-Reported Outcomes (CD-PRO) Questionnaire
    Higgins, Peter D.
    Harding, Gale
    Patrick, Donald L.
    Revicki, Dennis A.
    Globe, Gary
    Viswanathan, Hema N.
    Trease, Sarah
    Fitzgerald, Kristina
    Borie, Dominique C.
    Leidy, Nancy K.
    [J]. GASTROENTEROLOGY, 2013, 144 (05) : S768 - S768
  • [2] MINIMAL CLINICALLY IMPORTANT DIFFERENCE (MCID) FOR THE CROHN'S DISEASE PATIENT-REPORTED OUTCOMES SIGNS AND SYMPTOMS (CD-PRO/SS) TOOL
    Jacob-Moffatt, Rhian
    Galloway, Deanna
    Hassanali, Azra
    Devine, Jacob
    Sharafali, Zaineb
    Musselman, David
    Matsui, Alison
    [J]. GASTROENTEROLOGY, 2022, 162 (07) : S232 - S232
  • [3] Defining Responders for the Crohn's Disease Patient-Reported Outcomes Signs and Symptoms (CD-PRO/SS) Tool Using Data From Patients Treated With Etrolizumab
    Higgins, Peter
    DeBusk, Kendra
    Jacob, Rhian
    Hassanali, Azra
    Sharafali, Zaineb
    Oh, Young
    Kadva, Alysha
    Matsui, Alison
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S9 - S9
  • [4] Development and validation of the ulcerative colitis patient-reported outcomes signs and symptoms (UC-PRO/SS) diary
    Higgins P.D.R.
    Harding G.
    Revicki D.A.
    Globe G.
    Patrick D.L.
    Fitzgerald K.
    Viswanathan H.
    Donelson S.M.
    Ortmeier B.G.
    Chen W.H.
    Leidy N.K.
    Debusk K.
    [J]. Journal of Patient-Reported Outcomes, 2 (1)
  • [5] Patient-Reported Impact of Symptoms in Crohn's Disease
    Varma, Anika
    Weinstein, Jennifer
    Seabury, Jamison
    Rosero, Spencer
    Wagner, Ellen
    Zizzi, Christine
    Luebbe, Elizabeth
    Dilek, Nuran
    McDermott, Michael
    Heatwole, John
    Saubermann, Lawrence
    Temple, Larissa
    Rogoff, Scott
    Heatwole, Chad
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (12): : 2033 - 2045
  • [6] Psychometric Evaluation of the Signs and Symptoms Modules of the Ulcerative Colitis Patient-Reported Outcomes Measure (UC-Pro/SS)
    Higgins, Peter
    Harding, Gale
    Patrick, Donald L.
    Revicki, Dennis A.
    Chen, Wen-Hung
    Globe, Gary
    Viswanathan, Hema N.
    Fitzgerald, Kristina
    Trease, Sarah
    Borie, Dominic
    Ortmeier, Brian G.
    Leidy, Nancy K.
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S451 - S451
  • [7] Development of novel patient-reported outcomes (PRO) instruments to assess atopic dermatitis signs, symptoms and impacts
    Curry, Christina
    Gauthier, Martha
    Cala, Mary Lynn
    Egan, Shayna
    Witherspoon, Brooke
    Evans, Christopher
    Fitzgerald, Kristina
    [J]. QUALITY OF LIFE RESEARCH, 2015, 24 : 158 - 158
  • [8] DEVELOPMENT AND VALIDATION OF PATIENT-REPORTED OUTCOMES (PRO) TOOL FOR EYELASH CHARACTERISTICS
    Hammond, G. C.
    Burgess, S. M.
    Cole, J. C.
    Yang, M.
    Hansen, J. E.
    Walt, J. G.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A78 - A78
  • [9] Minimal Clinically Important Difference (MCID) for the Ulcerative Colitis Patient-Reported Outcomes Signs and Symptoms (UC-PRO/SS) Tool
    Pulley, J.
    Galloway, D.
    Oh, Y.
    Devine, J.
    Petrek, H.
    Khavarian, A.
    Matsui, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S197 - S198
  • [10] Patient-Reported Outcomes in Crohn’s Disease: Does Race Matter?
    Sara Horst
    [J]. Digestive Diseases and Sciences, 2014, 59 : 2354 - 2356